Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rhakoss Spinal Implant May Be Safer Alternative To Allograft – Orthovita

This article was originally published in The Gray Sheet

Executive Summary

Orthovita is emphasizing its Rhakoss synthetic bone spinal implant as a potentially safer alternative to allograft for cervical spinal fusion surgery

You may also be interested in...



Orthovita Rhakoss

Orthopedic biomaterials manufacturer plans to file for a CE mark by year end, following completed enrollment of 70 cervical spinal fusion patients in a nine-site pivotal trial. Patients will be followed for six months. The synthetic bone spinal implant is a potentially safer alternative to allograft for cervical spinal fusion surgery, Orthovita contends (1"The Gray Sheet" Aug. 26, 2002, p. 28)...

Orthovita Rhakoss

Orthopedic biomaterials manufacturer plans to file for a CE mark by year end, following completed enrollment of 70 cervical spinal fusion patients in a nine-site pivotal trial. Patients will be followed for six months. The synthetic bone spinal implant is a potentially safer alternative to allograft for cervical spinal fusion surgery, Orthovita contends (1"The Gray Sheet" Aug. 26, 2002, p. 28)...

Orthovita Cortoss

Synthetic cortical bone void filler receives CE mark for vertebral augmentation, including compression fractures caused by osteoporosis and invasive tumors. Patient enrollment for a 20-patient, U.S. pilot trial assessing Cortoss for vertebral augmentation began early this year. Advantages over PMMA bone cement include improved visualization and reduced risk of thermal tissue damage (1"The Gray Sheet" Aug. 26, 2002, p. 28)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel